Approval from Health Canada to expand Serenta Registrational Phase 3 trial in FAP and Update on Serenta Progress
Biodexa Pharmaceuticals PLC June 29, 2026 Approval from Health Canada to expand Serenta Registrational Phase 3 trial in…
#Canada #BiodexaPharmaceuticalsPLC #CancerPrevention #CPRIT #FamilialAdenomatousPolyposis #FAPpatients #HealthCanada #mammalianTargetOfRapamycin #mTORinhibitor #polypsinthecolon #Serenta
https://www.europesays.com/canada/108531/